HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension
CONCLUSIONS: Our findings indicate that targeting HMGB2 might be a novel therapeutic strategy for treating PH. Serum HMGB2 levels could serve as a novel biomarker for diagnosing PA hypertension and determining its prognosis.PMID:38572649 | DOI:10.1161/ATVBAHA.123.319916
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Deping Kong Jing Liu Junmi Lu Cheng Zeng Hao Chen Zhenzhen Duan Ke Yu Xialei Zheng Pu Zou Liufang Zhou Yicheng Lv Qingye Zeng Lin Lu Jiang Li Yuhu He Source Type: research
More News: Arteriosclerosis | Biology | Cancer | Cancer & Oncology | Cardiology | Hypertension | Molecular Biology | Pulmonary Hypertension | Pulmonary Thromboembolism | Thrombosis